These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 2244801)

  • 1. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 2. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 5. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 6. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific [3H]raclopride binding to neostriatal dopamine D2 receptors: role of disulfide and sulfhydryl groups.
    Reader TA; Molina-Holgado E; Lima L; Boulianne S; Dewar KM
    Neurochem Res; 1992 Aug; 17(8):749-59. PubMed ID: 1379349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes.
    Hall H; Wedel I; Halldin C; Kopp J; Farde L
    J Neurochem; 1990 Dec; 55(6):2048-57. PubMed ID: 1977888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T; Stockmeier CA; Overholser JC; Thompson PA; Meltzer HY
    Brain Res; 1995 May; 681(1-2):109-16. PubMed ID: 7552267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Adv Biochem Psychopharmacol; 1980; 21():443-50. PubMed ID: 6246753
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinetic analysis of receptor binding with positron emission tomography.
    Eriksson L; Farde L; Rosenquist G
    Acta Radiol Suppl; 1991; 376():126-7. PubMed ID: 1666746
    [No Abstract]   [Full Text] [Related]  

  • 15. No D2 receptor increase in PET study of schizophrenia.
    Farde L; Wiesel FA; Hall H; Halldin C; Stone-Elander S; Sedvall G
    Arch Gen Psychiatry; 1987 Jul; 44(7):671-2. PubMed ID: 2955770
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.
    Smith GS; Dewey SL; Brodie JD; Logan J; Vitkun SA; Simkowitz P; Schloesser R; Alexoff DA; Hurley A; Cooper T; Volkow ND
    Am J Psychiatry; 1997 Apr; 154(4):490-6. PubMed ID: 9090335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride.
    Antonini A; Leenders KL
    Ann N Y Acad Sci; 1993 Sep; 695():81-5. PubMed ID: 8239318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors.
    Rinne JO; Hublin C; Partinen M; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Laihinen A
    Neurology; 1995 Sep; 45(9):1735-8. PubMed ID: 7675236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P; Guan HC; Van Tol HH
    Nature; 1993 Sep; 365(6445):441-5. PubMed ID: 8413587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.